PRF Technologies (PRFX) Change in Accured Expenses (2023 - 2024)
PRF Technologies (PRFX) recorded quarterly Change in Accured Expenses of $9000.0 in Q4 2024, down 92.37% on a QoQ basis from $118000.0 in Q4 2023, and down 92.37% year-over-year from $118000.0 in Q1 2024.
PRF Technologies (PRFX) Change in Accured Expenses (2023 - 2024) Analysis & Trends
PRF Technologies has disclosed Change in Accured Expenses across 2 years of filings, most recently posting $9000.0 for Q4 2024.
- Quarterly Change in Accured Expenses fell 92.37% year-over-year to $9000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $9000.0 (down 92.37% YoY) and the FY2025 annual result came in at $113000.0, up 1155.56% from the prior year.
- Change in Accured Expenses fell to $9000.0 in Q4 2024, from $118000.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $118000.0 in Q4 2023 and troughed at $9000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -144.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -234.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -12.70 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -14.30 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 4.89 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 10.02 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 23.00 Mn |
| 10 | PRF Technologies | 933,081.16 | -2.46 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 9,000.00 |
| Dec 31, 2024 | 9,000.00 |
| Dec 31, 2023 | 118,000.00 |
| Dec 31, 2023 | 118,000.00 |